RESEARCH: HALOGENASES
FOLDING PROJECT #19212 PROFILE

Lots of medicines use halogens (like fluorine and chlorine). Adding these to drugs is tricky because it can be hard to control where they go. The project relates to using computer models to predict how enzymes called halogenases add halogens to different molecules, so we can make medicine production safer and more precise.

Note: This TLDR is a simplication and may not be 100% accurate.

Approximately 40 percent of drugs approved or currently in clinical testing contain halogens (F, Cl, Br, or I) as pharmaceutically active ligand substituents.

This makes the halogenation of chemical scaffolds an issue of particular interest to medicinal chemists when attempting to synthesize potential drug candidates.

Many of the current methods for halogenation are difficult to control the regioselectivity or produce toxic byproducts during the reaction.

Due to these issues; halogenases, a class of enzymes that catalyze highly regioselective halogenation of various molecules in nature, have been studied as a means to improve existing halogenation methods with less toxic byproducts and higher regioselectivity of reaction.

By utilizing Relative Binding Free Energy calculations (RBFE) across a number of common organic molecule scaffolds, our goal is to better predict the probability and site of halogenation for various common chemical scaffolds across a number of halogenases.

---

Halogens

Elements fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

Halogens are highly reactive elements commonly used in pharmaceutical drug development. They can be added to molecules to alter their properties and enhance their effectiveness as drugs. However, controlling the location and amount of halogenation during synthesis can be challenging.

---

Ligand

A molecule that binds to a specific target (e.g., receptor, enzyme).

In drug development, ligands are molecules designed to bind to specific targets within the body, such as proteins or receptors. This binding can trigger various effects, leading to therapeutic outcomes.

---

Pharmaceutically Active

Having a biological effect that can be used in medicine.

This term describes substances that have the potential to treat or prevent diseases. Pharmaceutically active compounds are the basis for medications and are rigorously tested for safety and efficacy.

---

Halogenase

An enzyme that catalyzes the addition of a halogen atom to a molecule.

Halogenases are enzymes found in nature that can add halogens (fluorine, chlorine, bromine, iodine) to various organic molecules. They offer a promising alternative to traditional chemical methods for halogenation due to their high regioselectivity and reduced toxicity.

---

Regioselective

Describes a reaction that preferentially forms one specific isomer over others.

Regioselectivity refers to the preference of a chemical reaction to produce a particular isomer (a molecule with the same atoms but different arrangement). In halogenation, regioselective enzymes ensure that halogens are added at desired positions on molecules.

---

Relative Binding Free Energy (RBFE)

A computational method for predicting the binding affinity of molecules to a target.

RBFE calculations are used in drug discovery to estimate how strongly a molecule will bind to its intended target (e.g., a protein). This information helps researchers identify promising drug candidates.